Principal Investigator

Khalid
Matin
Awardee Organization

Virginia Commonwealth University
United States

Fiscal Year
2023
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

VCU Massey Cancer Center Minority/Underserved NCI Community Oncology Research Program

Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) will serve as the primary component site for an NCORP Minority/Underserved Community Site (MU-NCORP) UG1 award in partnership with 6 collaborating community affiliate sites in the Commonwealth of Virginia. Over 30% of patients seen in the MCC MU-NCORP are from minority populations, primarily African Americans. This proposal emphasizes the unique urban and rural population available to the MCC MU-NCORP, the history of extensive participation by primary health care providers and specialists, in particular, surgeons, pediatric/AYA oncologists, gynecologic surgeons, radiation oncologists, neuro-oncologists, and medical oncologists in clinical research, and VCU initiatives in cancer outreach conducted at rural sites across Virginia. This community-based NCORP, focused on participation in clinical research of minority populations, was initially funded as a Minority-Based Community Clinical Oncology Program in 1990 and has been continuously funded, including since 2014 as a MU-NCORP. The MCC MU-NCORP has affiliations with 5 Research Bases (Alliance for Clinical Trials in Oncology, Children’s Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and the Wake Forest NCORP Research Base). Our application describes the working relationships with the Research Bases and the focus of the MCC MU-NCORP to accrue significant numbers of minority participants in cancer control and prevention, treatment/imaging, and cancer care delivery clinical research studies. Working relationships of the primary site’s investigators, research staff, and support personnel with the affiliate sites are also described. Accordingly, the specific aims of this proposal are (1) to increase the overall enrollment of racial/ethnic and rural populations in our catchment areas to NCI-approved studies, with a greater focus on cancer control research, cancer prevention research, and cancer care delivery research (CCDR), in addition to cancer treatment research; (2) to collaborate with the NCORP Research Bases by (i) providing insight into relevance for community practices during concept development, (ii) identifying care disparities our catchment areas that should be studied, and (iii) providing input on feasibility during concept and protocol development; (3) to exceed the required annual minimum participation in CCDR protocols; (4) to participate in biospecimen collection for biobanks that serve as scientific resources for NCORP Research Bases; and (5) to participate in NCORP initiatives, such as DCP-001, to document screening efforts for clinical trial enrollment and to address cancer health disparities. The proposed research is relevant to the mission of the NCI as MCC and the community affiliates will bring cancer clinical trials and research to low-income, minority, and medically underserved individuals who otherwise would not have access to such studies. Targeting the minority/underserved populations in their communities is a critical step toward alleviating the cancer care disparities prevalent in these populations.

Publications

  • Hoetger C, Bono RS, Nicksic NE, Barnes AJ, Cobb CO. Influence of Electronic Cigarette Characteristics on Susceptibility, Perceptions, and Abuse Liability Indices among Combustible Tobacco Cigarette Smokers and Non-Smokers. International journal of environmental research and public health. 2019 May 23;16. (10). PMID: 31126016
  • Nicksic NE, Do EK, Barnes AJ. Cannabis legalization, tobacco prevention policies, and Cannabis use in E-cigarettes among youth. Drug and alcohol dependence. 2020 Jan 1;206:107730. Epub 2019 Nov 10. PMID: 31759233
  • Nicksic NE, Barnes AJ. Is susceptibility to E-cigarettes among youth associated with tobacco and other substance use behaviors one year later? Results from the PATH study. Preventive medicine. 2019 Apr;121:109-114. Epub 2019 Feb 16. PMID: 30776386
  • Nicksic NE, Brosnan PG, Chowdhury N, Barnes AJ, Cobb CO. "Think it. Mix it. Vape it.": A Content Analysis on E-Cigarette Radio Advertisements. Substance use & misuse. 2019;54(8):1355-1364. Epub 2019 Mar 12. PMID: 30860933
  • Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. The New England journal of medicine. 2019 Jun 20;380(25):2395-2405. Epub 2019 Jun 3. PMID: 31157962
  • Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD, Le-Petross HT, Giuliano AE, Van Zee KJ, Hunt KK, Hahn OM, Carey LA, Partridge AH. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Jun 10;41(17):3184-3193. Epub 2023 Mar 28. PMID: 36977292
  • Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. Journal of the National Cancer Institute. 2021 Apr 6;113(4):390-399. PMID: 32986828
  • Bear HD, McGuire KP. Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters. Annals of surgical oncology. 2019 Aug;26(8):2316-2318. Epub 2019 Apr 24. PMID: 31020504
  • Barnes AJ, Bono RS, Rudy AK, Hoetger C, Nicksic NE, Cobb CO. Effect of e-cigarette advertisement themes on hypothetical e-cigarette purchasing in price-responsive adolescents. Addiction (Abingdon, England). 2020 Dec;115(12):2357-2368. Epub 2020 May 14. PMID: 32285978
  • Nicksic NE, Bono RS, Rudy AK, Cobb CO, Barnes AJ. Smoking status and racial/ethnic disparities in youth exposure to tobacco advertising. Journal of ethnicity in substance abuse. 2022 Jul-Sep;21(3):959-974. Epub 2020 Sep 11. PMID: 32915098
  • Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. 2019 Oct 1;125(19):3378-3389. Epub 2019 Jun 7. PMID: 31174236
  • Bottinor WJ, Flamand Y, Haas NB, ONeill AM, DiPaola RS, Subramanian P, Cella D, Hundley WG, Wagner LI, Salsman JM, Ky B. Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805. Journal of the National Comprehensive Cancer Network : JNCCN. 2023 Jul;21(7):725-731.e1. PMID: 37433436
  • Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Nov 1;28(11):2806-2812. PMID: 28945884
  • Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Oct 10;37(29):2620-2631. Epub 2019 Aug 13. PMID: 31408415
  • Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 15;25(2):524-532. Epub 2018 Nov 12. PMID: 30420448
  • Hoetger C, Wall CSJ, Rudy AK, Nicksic NE, Bhatt SM, Sey NYA, Khan M, Braxton D, Barnes AJ, Cobb CO. Content appealing to youth and spend characteristics of electronic cigarette video advertisements. Journal of public health (Oxford, England). 2022 Mar 7;44(1):129-137. PMID: 33300577
  • Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine. 2023 Mar 2;388(9):813-823. PMID: 36856617
  • Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 Apr 4;133(14):1548-1559. Epub 2019 Jan 18. PMID: 30658992
  • Nicksic NE, Snell LM, Barnes AJ. Reasons to use e-cigarettes among adults and youth in the Population Assessment of Tobacco and Health (PATH) study. Addictive behaviors. 2019 Jun;93:93-99. Epub 2019 Jan 24. PMID: 30703668
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine. 2018 Jul 12;379(2):111-121. Epub 2018 Jun 3. PMID: 29860917
  • Rosenbaum CA, Jung SH, Pitcher B, Bartlett NL, Smith SM, Hsi E, Wagner-Johnston N, Thomas SP, Leonard JP, Cheson BD. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). British journal of haematology. 2019 Apr;185(1):53-64. Epub 2019 Feb 5. PMID: 30723894
  • Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, Tevaarwerk AJ, Carlos RC, Albain KS, Olson JA Jr, Goetz MP, Pritchard KI, Hayes DF, Geyer CE, Dees EC, McCaskill-Stevens WJ, Minasian LM, Sledge GW Jr, Cella D. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jun 10;38(17):1875-1886. Epub 2020 Apr 9. PMID: 32271671
  • Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Annals of surgical oncology. 2017 Jul;24(7):1853-1860. Epub 2016 Nov 18. PMID: 27864694
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine. 2015 Nov 19;373(21):2005-14. Epub 2015 Sep 27. PMID: 26412349
  • Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood advances. 2017 Jan 24;1(5):331-340. PMID: 29034366